DICE Therapeutics, Inc. (NASDAQ:DICE) Receives $62.40 Consensus Target Price from Brokerages

DICE Therapeutics, Inc. (NASDAQ:DICE – Get Free Report) has been assigned an average recommendation of “Hold” from the thirteen brokerages that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among […]

Related Keywords

Johnr Jacobsen , ,Ameritas Advisory Services ,Dice Therapeutics Inc ,Northpond Ventures Gp Llc ,Cantor Fitzgerald ,Tower Research Capital ,Life Insurance Co ,Nasdaq ,Wells Fargo Company ,Investment Advisers ,Securities Exchange Commission ,Therapeutics Inc ,Canaccord Genuity Group ,Longfellow Investment Management Co ,Get Free Report ,Genuity Group ,Exchange Commission ,Investment Management ,Advisory Services ,Research Capital ,Metropolitan Life Insurance ,Life Insurance ,Get Free ,Dice Therapeutics ,Nasdaq Dice ,Dice ,Medical ,Ratings ,Consensus ,